PCSA
Processa Pharmaceuticals, Inc. [PCSA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PCSA Stock Summary
In the News
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that George Ng, Chief Executive Officer, will present a corporate update at the MedInvest Biotech and Pharma Investor Conference. David Young, Processa's President of Research & Development, will participate virtually.
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that the Company will have two posters at the American Association for Cancer Research Annual Meeting 2024 in San Diego from April 5-10, 2024.
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Chief Executive Officer George Ng will present a corporate update at the 2024 BIO CEO & Investor Conference being held on February 26 – 27, 2024 at the Marriott Marquis in New York City.
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces that CEO George Ng will present a corporate update at The Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference being held February 20 – 23, 2024.
Why Is Processa Therapeutics (PCSA) Stock Up 90% Today?
Clinical-stage pharmaceutical company Processa Therapeutics (NASDAQ: PCSA ) — which specializes in the field of oncology — is skyrocketing on Thursday. PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today.
What made Processa Pharmaceuticals stock nearly triple on Thursday?
Processa Pharmaceuticals Inc (NASDAQ: PCSA) says it has completed a safety evaluation of its cancer treatment. Its shares rallied well over 150% on Thursday.
Processa Pharmaceuticals to Present at the Biotech Showcase 2024
HANOVER, MD, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that George Ng, Chief Executive Officer, will present a corporate overview at the Biotech Showcase 2024. The event is being held at the Hilton San Francisco Union Square on January 8 – 10, 2024.
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
HANOVER, MD, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Dr. David Young, President of Research and Development, will present virtually at the MedInvest Oncology Investor Conference.
Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
HANOVER, MD, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Dr. David Young, President of Research and Development, will present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas.
Best Penny Stocks Under $1? 4 To Watch This Week
What are the best penny stocks under $1? If you saw this headline, that's probably a question you have heading into the second half of the week.
PCSA Financial details
PCSA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -12.15 | -38.44 | -14.92 | -68.1 | -8.48 | |
| Operating cash flow per share | -9.95 | -8.38 | -11.38 | -11.92 | -6.15 | |
| Free cash flow per share | -9.95 | -8.38 | -11.38 | -11.92 | -6.15 | |
| Cash per share | 2.5 | 41.11 | 21.54 | 8.07 | 3.59 | |
| Book value per share | 29 | 61.17 | 33.27 | 9.28 | 3.8 | |
| Tangible book value per share | -5.9 | 37.58 | 22.75 | 9.28 | 3.8 | |
| Share holders equity per share | 29 | 61.17 | 33.27 | 9.28 | 3.8 | |
| Interest debt per share | 3.85 | 1.62 | 0.1 | 0.16 | 0.11 | |
| Market cap | 99.46M | 49.46M | 75.07M | 17.72M | 8.77M | |
| Enterprise value | 99.8M | 34.37M | 58.65M | 11.45M | 4.22M | |
| P/E ratio | -29.62 | -3.43 | -6.57 | -0.32 | -0.79 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -36.17 | -15.74 | -8.61 | -1.84 | -1.09 | |
| PFCF ratio | -36.17 | -15.74 | -8.61 | -1.84 | -1.09 | |
| P/B Ratio | 12.41 | 2.16 | 2.95 | 2.37 | 1.76 | |
| PTB ratio | 12.41 | 2.16 | 2.95 | 2.37 | 1.76 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -31.98 | -6.11 | -5.45 | -0.94 | -0.37 | |
| EV to operating cash flow | -36.29 | -10.94 | -6.73 | -1.19 | -0.52 | |
| EV to free cash flow | -36.29 | -10.94 | -6.73 | -1.19 | -0.52 | |
| Earnings yield | -0.03 | -0.29 | -0.15 | -3.1 | -1.27 | |
| Free cash flow yield | -0.03 | -0.06 | -0.12 | -0.54 | -0.92 | |
| Debt to equity | 0.13 | 0.01 | 0 | 0.03 | 0.03 | |
| Debt to assets | 0.09 | 0.01 | 0 | 0.03 | 0.03 | |
| Net debt to EBITDA | -0.11 | 2.68 | 1.53 | 0.51 | 0.4 | |
| Current ratio | 0.85 | 13.27 | 18.87 | 8.4 | 7.71 | |
| Interest coverage | -107.36 | -53.84 | -33.52K | 271.99 | 0 | |
| Income quality | 0.82 | 0.22 | 0.76 | 0.35 | 0.73 | |
| Dividend Yield | 0 | 0.02 | 0 | 0 | 0 | |
| Payout ratio | 0 | -0.05 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.89 | 0.35 | 0.3 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | -12.5 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 89.05 | 230.02 | 105.68 | 119.21 | 26.94 | |
| ROIC | -0.36 | -0.6 | -0.45 | -6.94 | -2.2 | |
| Return on tangible assets | -2.71 | -0.88 | -0.62 | -6.36 | -1.92 | |
| Graham Net | -7.89 | 35.51 | 20.33 | 6.65 | 2.98 | |
| Working capital | -184.42K | 14.98M | 17.36M | 7.39M | 4.9M | |
| Tangible asset value | -1.63M | 14.09M | 17.43M | 7.47M | 4.99M | |
| Net current asset value | -1.86M | 13.93M | 17.35M | 7.24M | 4.84M | |
| Invested capital | 0.13 | 0.01 | 0 | 0.03 | 0.03 | |
| Average receivables | 10.79K | 115.88K | 151.01K | 35.14K | 0 | |
| Average payables | 183.86K | 198.15K | 269.8K | 273.23K | 319.58K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 31.44 | 7.73 | 6.59 | 4.34 | 512.34K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 11.61 | 47.2 | 55.43 | 84.03 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.42 | -0.63 | -0.45 | -7.34 | -2.23 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -42.93 | 0.15 | -1.94 | -1.54 | -1.87 | |
| Operating cash flow per share | -3.11 | -1.86 | -1.53 | -1.3 | -1.65 | |
| Free cash flow per share | -3.11 | -1.86 | -1.53 | -1.31 | -1.65 | |
| Cash per share | 8.11 | 9.43 | 6.44 | 5.08 | 3.66 | |
| Book value per share | 9.32 | 8.91 | 6.8 | 5.31 | 3.88 | |
| Tangible book value per share | 9.32 | 8.91 | 6.8 | 5.31 | 3.88 | |
| Share holders equity per share | 9.32 | 8.91 | 6.8 | 5.31 | 3.88 | |
| Interest debt per share | 10.68 | -3.49 | 0.14 | 0.13 | 0.12 | |
| Market cap | 17.64M | 11.39M | 13.41M | 6.75M | 8.6M | |
| Enterprise value | 11.36M | 854.31K | 4.93M | 61.57K | 4.05M | |
| P/E ratio | -0.13 | 17.05 | -1.28 | -0.81 | -0.89 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -7.06 | -5.39 | -6.5 | -3.83 | -4.05 | |
| PFCF ratio | -7.06 | -5.39 | -6.5 | -3.83 | -4.05 | |
| P/B Ratio | 2.36 | 1.12 | 1.46 | 0.94 | 1.72 | |
| PTB ratio | 2.36 | 1.12 | 1.46 | 0.94 | 1.72 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 6.82 | -0.21 | -1.82 | -0.03 | -1.64 | |
| EV to operating cash flow | -4.55 | -0.4 | -2.39 | -0.03 | -1.91 | |
| EV to free cash flow | -4.55 | -0.4 | -2.39 | -0.03 | -1.91 | |
| Earnings yield | -1.95 | 0.01 | -0.19 | -0.31 | -0.28 | |
| Free cash flow yield | -0.14 | -0.19 | -0.15 | -0.26 | -0.25 | |
| Debt to equity | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | |
| Debt to assets | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | |
| Net debt to EBITDA | -3.77 | 2.57 | 3.13 | 3.09 | 1.84 | |
| Current ratio | 8.4 | 5.65 | 12.05 | 9.57 | 7.71 | |
| Interest coverage | 0.18 | 0.98 | 0 | 0 | 0 | |
| Income quality | 0.19 | 0.53 | 0.79 | 0.85 | 0.88 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | -33.85 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 94.86 | 5.42 | 17.23 | 13.57 | 12.78 | |
| ROIC | 0.49 | 0.02 | -0.28 | -0.59 | -0.47 | |
| Return on tangible assets | -3.99 | 0.01 | -0.26 | -0.26 | -0.42 | |
| Graham Net | 6.68 | 7.42 | 5.75 | 4.4 | 3.04 | |
| Working capital | 7.39M | 10.06M | 9.08M | 7.08M | 4.9M | |
| Tangible asset value | 7.47M | 10.14M | 9.16M | 7.17M | 4.99M | |
| Net current asset value | 7.24M | 9.93M | 8.97M | 6.99M | 4.84M | |
| Invested capital | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 319.31K | 322.13K | 277.87K | 292.66K | 328.96K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 136.15 | 6.94 | 7.92 | 14.38 | 200.33K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.66 | 12.96 | 11.36 | 6.26 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -4.61 | 0.02 | -0.29 | -0.29 | -0.48 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
PCSA Frequently Asked Questions
What is Processa Pharmaceuticals, Inc. stock symbol ?
Processa Pharmaceuticals, Inc. is a US stock , located in Hanover of Md and trading under the symbol PCSA
What is Processa Pharmaceuticals, Inc. stock quote today ?
Processa Pharmaceuticals, Inc. stock price is $1.52 today.
Is Processa Pharmaceuticals, Inc. stock public?
Yes, Processa Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.71M
- Market Capitalization 4.77M
- Employee 13
- CEO Mr. George K. Ng Esq., J.D.
- Headquarters Hanover,MD,US
- IPO Date 2014-03-07
-
Website
https://www.processapharmaceuticals.com 
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
